Analyzing AngioSoma (OTCMKTS:SOAN) and Qualigen Therapeutics (NASDAQ:AIXC)

AngioSoma (OTCMKTS:SOAN) and Qualigen Therapeutics (NASDAQ:AIXC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Profitability

This table compares AngioSoma and Qualigen Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AngioSoma	N/A	N/A	-1,245.34%
Qualigen Therapeutics	N/A	-771.52%	-79.52%

Risk & Volatility

AngioSoma has a beta of -0.46, meaning that its stock price is 146% less volatile than the S&P 500. Comparatively, Qualigen Therapeutics has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for AngioSoma and Qualigen Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AngioSoma	0	0	0	0	0.00
Qualigen Therapeutics	1	0	0	0	1.00

Given AngioSoma’s higher probable upside, equities research analysts plainly believe AngioSoma is more favorable than Qualigen Therapeutics.

Earnings and Valuation

This table compares AngioSoma and Qualigen Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AngioSoma	N/A	N/A	-$540,000.00	N/A	N/A
Qualigen Therapeutics	N/A	N/A	-$16.97 million	($6.47)	-0.23

Institutional & Insider Ownership

0.0% of AngioSoma shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 1.2% of Qualigen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Qualigen Therapeutics beats AngioSoma on 5 of the 8 factors compared between the two stocks.

About AngioSoma

AngioSoma, Inc., a wellness company, engages in the development and commercialization of dietary supplements to the medical, wellness, and adult-use markets. The company was founded in 2016 and is based in Houston, Texas.

About Qualigen Therapeutics

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient’s blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.